Headlines about Akorn (NASDAQ:AKRX) have been trending somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Akorn earned a news sentiment score of 0.01 on Accern’s scale. Accern also assigned media stories about the company an impact score of 44.7905606943794 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the media stories that may have impacted Accern’s rankings:
Several research analysts have issued reports on AKRX shares. Piper Jaffray reissued a “hold” rating on shares of Akorn in a research report on Monday, April 23rd. Craig Hallum dropped their target price on Akorn from $34.00 to $14.00 and set a “hold” rating on the stock in a research report on Monday, April 23rd. Deutsche Bank reissued a “hold” rating on shares of Akorn in a research report on Thursday, April 12th. BidaskClub raised Akorn from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 21st. Finally, TheStreet cut Akorn from a “c-” rating to a “d” rating in a research report on Friday, May 4th. Two equities research analysts have rated the stock with a sell rating and seven have given a hold rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $28.20.
NASDAQ AKRX opened at $14.03 on Monday. The company has a debt-to-equity ratio of 1.01, a quick ratio of 3.37 and a current ratio of 4.64. Akorn has a 52 week low of $10.76 and a 52 week high of $33.95. The stock has a market capitalization of $1.76 billion, a PE ratio of 8.71, a P/E/G ratio of 1.15 and a beta of 1.71.
Akorn, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health.
Receive News & Ratings for Akorn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn and related companies with MarketBeat.com's FREE daily email newsletter.